


What is claimed is:

1. A compound according to formula (I) hereinbelow:



5 wherein:

R₁ represents NR₄R₅;

R₂ represents CONH₂ or SO₂NH₂;

R₃ represents up to three substituents selected from the group consisting of halogen, C₁₋₄alkyl, NH₂, CF₃, OCF₃, O-alkyl, S-alkyl, CN, CHO, SO₂-alkyl, and NO₂;

10 R₄ represents H, C₁₋₂ alkyl;

R₅ represents C(=A)NHR₆, COR₇, or R₆;

A represents O, S, or N;

R₆ represents H, or C₁₋₂ alkyl;

15 R₇ represents C₁₋₂ alkyl;

L represents a linker D-E-D such that

D represents a bond or C₁₋₄ alkyl;



20 E represents C = C, CONH, NHCO, COO, N, O, S, or \equiv ; and

G and I independently represent H, C₁₋₂ alkyl; or a pharmaceutically acceptable salt thereof, provided that the compound of formula (I) is not 2-[(aminocarbonyl)amino]-5-[(4-chlorophenyl)methyl]oxyl-3-thiophenecarboxamide.

25 2. A compound according to claim 1 wherein R₂ is CONH₂.

3. A compound according to claim 1 wherein R₅ is C(=A)NHR₆.

4. A compound according to claim 1 wherein A is O.

5. A compound according to claim 1 wherein E is



6. A compound according to claim 1 wherein the compound is selected from the group consisting of:

- 10 5-[(E)-phenyl]-ethenyl]-2-ureido-thiophene-3-carboxylic acid amide;
5-[(E)-2-(4-Fluoro-phenyl)- ethenyl]-2-ureido-thiophene-3-carboxylic acidamide;
5-[(E)-2-(4-Chloro-phenyl)- ethenyl]-2-ureido-thiophene-3-carboxylic acid amide;
5-Phenethyl-2-ureido-thiophene-3-carboxylic acid amide;
5-Benzyl-2-ureido-thiophene-3-carboxylic acid amide;
15 5-(1-Phenyl-ethyl)-2-ureido-thiophene-3-carboxylic acid amide;
5-Phenylethynyl-2-ureido-thiophene-3-carboxylic acid amide;
5-(4-Fluorophenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;
5-(4-Ethylphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;
5-(4-Methoxyphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;
20 5-(4-Chlorophenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide ;
5-(4-Trifluoromethylphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;
5-(3-Trifluoromethylphenylethynyl)-2-ureido-thiophene-3-carboxylic acid amide;
and
5-Acetylamino-thiophene-2,4-dicarboxylic acid 4-amide 2-[(3-chloro-phenyl)-
25 amide]; or a pharmaceutically acceptable salt thereof.

7. A method of treating a disease characterized by pathological NF- κ B activation comprising inhibiting the pathological activation by administering to a patient in need thereof an effective amount of a compound according to claim 1.

8. A method according to claim 7 wherein the disease is an inflammatory or tissue repair disorder.
9. A method according to Claim 8 wherein the disease is selected from the group consisting of inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease) osteoarthritis, osteoporosis and fibrotic diseases, dermatosis, including psoriasis, atopic dermatitis and ultraviolet radiation (UV)-induced skin damage, autoimmune diseases including systemic lupus erythematosus, multiple sclerosis, psoriatic arthritis, alkylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, including Hodgkins disease, cachexia, inflammation associated with infection and certain viral infections, including acquired immune deficiency syndrome (AIDS), adult respiratory distress syndrome, and Ataxia Telangiectasia.
10. A method according to claim 7 wherein said disease is COPD.
11. A method according to claim 7 wherein said disease is asthma.
12. A method according to claim 7 wherein said disease is rheumatoid arthritis.
13. A method according to claim 7 wherein said disease is dermatosis.
14. A method according to claim 7 wherein the disease is selected from the group consisting of: psoriasis, atopic dermatitis, and UV-induced skin damage.
15. A method according to claim 7 wherein the disease is selected from the group consisting of autoimmune diseases; tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, osteoarthritis, osteoporosis, and Ataxia Telangiectasia.

16. A method according to claim 7 wherein said disease is an autoimmune disease.
17. A method according to claim 9 wherein the autoimmune disease is systemic lupus erythematosus, multiple sclerosis, psoriatic arthritis, or ankylosing spondylitis, diabetes
18. A method according to claim 7 wherein the disease is cancer and/or cachexia.
19. A method according to claim 7 wherein the cancer is Hodgkin's disease.
- 10 20. A method according to claim 7 wherein the disease is inflammation associated with infection and certain viral infections, including acquired immune deficiency syndrome (AIDS).
- 15 21. A method according to claim 7 wherein the disease is AIDS.
22. A method according to claim 7 wherein the disease is adult respiratory distress syndrome.